OxyContin Generics From Endo And Teva Will Include Risk Management Plans
Executive Summary
Risk management programs for Endo's and Teva's generic versions of OxyContin reflect differences in the nature of generic marketing compared to that for branded drugs
You may also be interested in...
Duragesic Risk Management Negotiations Ongoing After FDA Health Advisory
Creation of a risk management plan for Johnson & Johnson's Duragesic and generics could be the next regulatory step for the product after FDA's release of a Public Health Advisory on fentanyl overdoses
Duragesic Risk Management Negotiations Ongoing After FDA Health Advisory
Creation of a risk management plan for Johnson & Johnson's Duragesic and generics could be the next regulatory step for the product after FDA's release of a Public Health Advisory on fentanyl overdoses
Remoxy Time-Release Oxycodone Phase III Trial Planned For Year-End
Pain Therapeutics plans to initiate a Phase III trial for Remoxy, its time-release oxycodone, around year-end